Completed
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
NCT02452372
- Conditions
- Acute Intermittent Porphyria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +10 more
- Locations
-
- Clinical Trial Site Birmingham, Alabama, United States
- Clinical Trial Site San Francisco, California, United States
- Clinical Trial Site New York, United States
- Clinical Trial Site Galveston, Texas, United States